Growth factor binding to the pericellular matrix and its importance in tissue engineering

Advanced Drug Delivery Reviews

Volumn 59, Issue 13, 2007, Pages 1366-1381

  Macri, Lauren ^a   Silverstein, David ^b   Clark, Richard A F ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Cytokine; Extracellular matrix; Growth factor; Growth factor binding; Pericellular matrix; Tissue engineering

Indexed keywords

BIODEGRADATION; BIOMOLECULES; CELL GROWTH; PROTEINS; SYNTHESIS (CHEMICAL);

CELLULAR ACTIVITIES; CYTOKINE; EXTRACELLULAR MATRIX; GROWTH FACTOR BINDING; PERICELLULAR MATRIX;

TISSUE ENGINEERING;

BIGLYCAN; COLLAGEN; CYTOKINE; DECORIN; FIBRIN; FIBRINOGEN; FIBRONECTIN; GLYCOSAMINOGLYCAN; GROWTH FACTOR; HEPARAN SULFATE; OSTEONECTIN; PROTEOGLYCAN; TENASCIN; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR BETA; VITRONECTIN;

CELL PROLIFERATION; CYTOSKELETON; EXTRACELLULAR MATRIX; INFLAMMATION; LIVER CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; REVIEW; TISSUE ENGINEERING; TISSUE REGENERATION; WOUND HEALING;

ANIMALS; CELL-MATRIX JUNCTIONS; EXTRACELLULAR MATRIX PROTEINS; GLYCOSAMINOGLYCANS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEOGLYCANS; TISSUE ENGINEERING;

EID: 36048958903     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.08.015     Document Type: Review

References (178)

1. Clark R.A., Ghosh K., and Tonnesen M.G. Tissue engineering for cutaneous wounds. J. Invest. Dermatol. 127 5 (2007) 1018-1029
2. Supp D.M.a.B., and S.T. Engineered skin substitutes: practices and potentials. Clin. Dermatol. 23 (2005) 403-412
3. McClain S.A., et al. Mesenchymal cell activation is the rate-limiting step of granulation tissue induction. Am. J. Pathol. 149 4 (1996) 1257-1270
4. Singer A.J., and Clark R.A. Cutaneous wound healing. N. Engl. J. Med. 341 10 (1999) 738-746
5. Grinnell F., and Zhu M. Fibronectin degradation in chronic wounds depends on the relative levels of elastase, alpha1-proteinase inhibitor, and alpha2-macroglobulin. J. Invest. Dermatol. 106 2 (1996) 335-341
6. Ehrenreich M., and Ruszczak Z. Update on tissue-engineered biological dressings. Tissue Eng. 12 9 (2006) 2407-2424
7. MacNeil S. Progress and opportunities for tissue-engineered skin. Nature 445 7130 (2007) 874-880
8. Marneros A.G., and Olsen B.R. Physiological role of collagen XVIII and endostatin. FASEB J. 19 7 (2005) 716-728
9. Droguett R., et al. Extracellular proteoglycans modify TGF-beta bio-availability attenuating its signaling during skeletal muscle differentiation. Matrix Biol. 25 6 (2006) 332-341
10. Hardingham T., and Bayliss M. Proteoglycans of articular cartilage: changes in aging and in joint disease. Semin. Arthritis Rheum. 20 3 Suppl 1 (1990) 12-33
11. Banerji S., et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J. Cell Biol. 144 4 (1999) 789-801
12. Toole B.P. Hyaluronan: from extracellular glue to pericellular cue. Nat. Rev., Cancer 4 7 (2004) 528-539
13. Itano N., et al. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J. Biol. Chem. 274 35 (1999) 25085-25092
14. Toole B.P. In: Hay E.D. (Ed). Proteoglycans and hyaluronan in morphogenesis and differentiation, in Cell Biology of the Extracellular Matrix (1991), Plenum Press, New York 305-341
15. Dowthwaite G., Edwards J., and Pitsillides A. An estential role for the interaction between hyaluronan and hyaluronan binding proteins during joint development. J. Histochem. Cytochem. 46 (1998) 641-651
16. Fraser J., Laurent T., and Laurent U. Hyaluronan: its nature, distribution, functions and turnover. J. Intern. Med. 242 (1997) 27-33
17. Cheung W., Crue T., and Turley E. Receptor for hyaluronan-mediated motility (RHAMM), a hyaladherin that regulates cell responses to growth factors. Biochem. Soc. Trans. 27 (1999) 135-142
18. Bently J.P. Rate of chondroitin sulfate formation in wound healing. Ann. Surg. 165 (1967) 186-191
19. Bronson R.E., Bertolami C.N., and Siebert E.P. Modulation of fibroblast growth and glycosaminoglycan synthesis by interleukin-1. Coll. Rel. Res. 7 (1987) 323-332
20. Welch M.P., Odland G.F., and Clark R.A.F. Temporal relationships of F-actin bundle formation, collagen and fibronectin matrix assembly, and fibronectin receptor expression to wound contraction. J. Cell Biol. 110 (1990) 133-145
21. Underhill C. CD44: the hyaluronan receptor. J. Cell Sci. 103 (1992) 293-298
22. Clark R.A.F., et al. Fibroblast invasive migration into fibronectin/fibrin gels requires a previously uncharacterized dermatan sulfate-CD44 proteoglycan. J. Invest. Dermatol. 122 2 (2004) 266-277
23. Turley E.A., Noble P.W., and Bourguignon L.Y. Signaling properties of hyaluronan receptors. J. Biol. Chem. 277 7 (2002) 4589-4592
24. Jackson D.G. The lymphatics revisited: new perspectives from the hyaluronan receptor LYVE-1. Trends Cardiovasc. Med. 13 1 (2003) 1-7
25. Huang S.S., et al. Cloning, expression, characterization, and role in autocrine cell growth of cell surface retention sequence binding protein-1. J. Biol. Chem. 278 44 (2003) 43855-43869
26. Boensch C., et al. Identification, purification, and characterization of cell-surface retention sequence-binding proteins from human SK-Hep cells and bovine liver plasma membranes. J. Biol. Chem. 270 4 (1995) 1807-1816
27. Houck K.A., et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 5 12 (1991) 1806-1814
28. LaRochelle W.J., et al. A novel mechanism regulating growth factor association with the cell surface: identification of a PDGF retention domain. Genes Dev. 5 7 (1991) 1191-1199
29. Ostman A., et al. Identification of a cell retention signal in the B-chain of platelet-derived growth factor and in the long splice version of the A-chain. Cell Regul. 2 7 (1991) 503-512
30. Iozzo R.V., and San Antonio J.D. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J. Clin. Invest. 108 3 (2001) 349-355
31. Ruoslahti E. Structure and biology of proteoglycans. Annu. Rev. Cell Biol. 4 (1988) 229-255
32. Gallagher J.T. The extended family of proteoglycans: social residents of the pericellular zone. Curr. Opin. Cell Biol. 1 6 (1989) 1201-1218
33. Hardingham T.E., and Fosang A.J. Proteoglycans: many forms and many functions. FASEB J. 6 3 (1992) 861-870
34. Bishop J.R., Schuksz M., and Esko J.D. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446 7139 (2007) 1030-1037
35. Ornitz D.M. FGFs, heparan sulfate and FGFRs: complex interactions essential for development. BioEssays 22 2 (2000) 108-112
36. Abraham J.A., and Klagsbrun M. Modulation of wound repair by members of the fibroblast growth factor family. In: Clark R.A.F. (Ed). The Molecular and Cellular Biology of Wound Repair (1996), Plenum Press, New York, NY 195-248
37. Basilico C., and Moscatelli D. The FGF family of growth factors and oncogenes. Adv. Cancer Res. 59 (1992) 115-165
38. Rapraeger A.C., et al. Regulation by heparan sulfate in fibroblast growth factor signaling. Methods Enzymol. 245 (1994) 219-240
39. Yayon A., and Klagsbrun M. Autocrine regulation of cell growth and transformation by basic fibroblast growth factor. Cancer Metastasis Rev. 9 3 (1990) 191-202
40. Ibrahimi O.A., et al. Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly. Biochemistry 43 16 (2004) 4724-4730
41. Pantoliano M.W., et al. Multivalent ligand-receptor binding interactions in the fibroblast growth factor system produce a cooperative growth factor and heparin mechanism for receptor dimerization. Biochemistry 33 34 (1994) 10229-10248
42. McKeehan W.L., Wang F., and Kan M. The heparan sulfate-fibroblast growth factor family: diversity of structure and function. Prog. Nucleic Acid Res. Mol. Biol. 59 (1998) 135-176
43. Szebenyi G., and Fallon J.F. Fibroblast growth factors as multifunctional signaling factors. Int. Rev. Cytol. Suppl. 185 (1999) 45-106
44. Rapraeger A.C. In the clutches of proteoglycans: how does heparan sulfate regulate FGF binding?. Chem. Biol. 2 10 (1995) 645-649
45. Forsten-Williams K., Chua C.C., and Nugent M.A. The kinetics of FGF-2 binding to heparan sulfate proteoglycans and MAP kinase signaling. J. Theor. Biol. 233 4 (2005) 483-499
46. Ruhrberg C., et al. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev. 16 20 (2002) 2684-2698
47. Gitay-Goren H., et al. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J. Biol. Chem. 267 9 (1992) 6093-6098
48. Catlow K., et al. Hepatocyte growth factor/scatter factor and its interaction with heparan sulphate and dermatan sulphate. Biochem. Soc. Trans. 31 2 (2003) 352-353
49. Lyon M., et al. Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. J. Biol. Chem. 269 15 (1994) 11216-11223
50. Lyon M., et al. Hepatocyte growth factor/scatter factor binds with high affinity to dermatan sulfate. J. Biol. Chem. 273 1 (1998) 271-278
51. Deakin J.A., and Lyon M. Differential regulation of hepatocyte growth factor/scatter factor by cell surface proteoglycans and free glycosaminoglycan chains. J. Cell Sci. 112 Pt 12 (1999) 1999-2009
52. Lyon M., Deakin J.A., and Gallagher J.T. The mode of action of heparan and dermatan sulfates in the regulation of hepatocyte growth factor/scatter factor. J. Biol. Chem. 277 2 (2002) 1040-1046
53. Raab G., and Klagsbrun M. Heparin-binding EGF-like growth factor. Biochim. Biophys. Acta 1333 3 (1997) F179-F199
54. Dugan T.A., et al. Decorin binds fibrinogen in a Zn2+-dependent interaction. J. Biol. Chem. 278 16 (2003) 13655-13662
55. Tufvesson E., and Westergren-Thorsson G. Tumour necrosis factor-alpha interacts with biglycan and decorin. FEBS Lett. 530 1-3 (2002) 124-128
56. Hyytiainen M., Penttinen C., and Keski-Oja J. Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation. Crit. Rev. Clin. Lab. Sci. 41 3 (2004) 233-264
57. Roberts A.B., and Sporn M.B. Transforming growth factor-beta. In: Clark R.A.F. (Ed). The Molecular and Cellular Biology of Wound Repair (1996), Plenum Press, New York, USA 275-310
58. Cabello-Verrugio C., and Brandan E. A novel modulatory mechanism of TGF-beta signaling through decorin and LRP-1. J. Biol. Chem. (2007)
59. Iozzo R.V. The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. J. Biol. Chem. 274 27 (1999) 18843-18846
60. Schonherr E., et al. Decorin, a novel player in the insulin-like growth factor system. J. Biol. Chem. 280 16 (2005) 15767-15772
61. Takeuchi Y., Kodama Y., and Matsumoto T. Bone matrix decorin binds transforming growth factor-beta and enhances its bioactivity. J. Biol. Chem. 269 51 (1994) 32634-32638
62. Riquelme C., et al. Antisense inhibition of decorin expression in myoblasts decreases cell responsiveness to transforming growth factor beta and accelerates skeletal muscle differentiation. J. Biol. Chem. 276 5 (2001) 3589-3596
63. Hausser H., et al. Selective inactivity of TGF-beta/decorin complexes. FEBS Lett. 353 3 (1994) 243-245
64. Schonherr E., et al. Decorin core protein fragment Leu155-Val260 interacts with TGF-beta but does not compete for decorin binding to type I collagen. Arch. Biochem. Biophys. 355 2 (1998) 241-248
65. Loots M.A., et al. Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur. J. Cell Biol. 81 3 (2002) 153-160
66. Blakytny R., et al. Lack of insulin-like growth factor 1 (IGF1) in the basal keratinocyte layer of diabetic skin and diabetic foot ulcers. J. Pathol. 190 5 (2000) 589-594
67. Ameye L., and Young M.F. Mice deficient in small leucine-rich proteoglycans: novel in vivo models for osteoporosis, osteoarthritis, Ehlers-Danlos syndrome, muscular dystrophy, and corneal diseases. Glycobiology 12 9 (2002) 107R-116R
68. Iozzo R.V. The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Crit. Rev. Biochem. Mol. Biol. 32 2 (1997) 141-174
69. Sankar S., et al. Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor beta 2. J. Biol. Chem. 270 22 (1995) 13567-13572
70. Lopez-Casillas F., et al. Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites. J. Cell Biol. 124 4 (1994) 557-568
71. Vilchis-Landeros M.M., et al. Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent. Biochem. J. 355 Pt 1 (2001) 215-222
72. Velasco-Loyden G., Arribas J., and Lopez-Casillas F. The shedding of betaglycan is regulated by pervanadate and mediated by membrane type matrix metalloprotease-1. J. Biol. Chem. 279 9 (2004) 7721-7733
73. Wu Y.J., et al. The interaction of versican with its binding partners. Cell Res. 15 7 (2005) 483-494
74. Yamagata M., et al. Selective distributions of proteoglycans and their ligands in pericellular matrix of cultured fibroblasts. Implications for their roles in cell-substratum adhesion. J. Cell Sci. 106 Pt 1 (1993) 55-65
75. Aspberg A., et al. The C-type lectin domains of lecticans, a family of aggregating chondroitin sulfate proteoglycans, bind tenascin-R by protein-protein interactions independent of carbohydrate moiety. Proc. Natl. Acad. Sci. U. S. A. 94 19 (1997) 10116-10121
76. Isogai Z., et al. Versican interacts with fibrillin-1 and links extracellular microfibrils to other connective tissue networks. J. Biol. Chem. 277 6 (2002) 4565-4572
77. Olin A.I., et al. The proteoglycans aggrecan and Versican form networks with fibulin-2 through their lectin domain binding. J. Biol. Chem. 276 2 (2001) 1253-1261
78. Hirose J., et al. Versican interacts with chemokines and modulates cellular responses. J. Biol. Chem. 276 7 (2001) 5228-5234
79. Pablos J.L., et al. Stromal-cell derived factor is expressed by dendritic cells and endothelium in human skin. Am. J. Pathol. 155 5 (1999) 1577-1586
80. Yan Q., and Sage E.H. SPARC, a matricellular glycoprotein with important biological functions. J. Histochem. Cytochem. 47 12 (1999) 1495-1506
81. Ingber D.E. Mechanical signaling and the cellular response to extracellular matrix in angiogenesis and cardiovascular physiology. Circ. Res. 91 10 (2002) 877-887
82. Ingber D.E. Tensegrity II. How structural networks influence cellular information processing networks. J. Cell Sci. 116 Pt 8 (2003) 1397-1408
83. Preissner K.T. Structure and biological role of vitronectin. Annu. Rev. Cell Biol. 7 (1991) 275-310
84. Pankov R., and Yamada K.M. Fibronectin at a glance. J. Cell Sci. 115 Pt 20 (2002) 3861-3863
85. Yamada K.M., and Clark R.A.F. Provisional matrix. In Molecular and Cellular Biology of Wound Repair (1996), Plenum
86. Chernousov M.A., et al. Role of the I-9 and III-1 modules of fibronectin in formation of an extracellular fibronectin matrix. J. Biol. Chem. 266 17 (1991) 10851-10858
87. Mao Y., and Schwarzbauer J.E. Stimulatory effects of a three-dimensional microenvironment on cell-mediated fibronectin fibrillogenesis. J. Cell Sci. 118 Pt 19 (2005) 4427-4436
88. Cavani A., et al. Distinctive integrin expression in the newly forming epidermis during wound healing in humans. J. Invest. Dermatol. 101 4 (1993) 600-604
89. Clark R.A., et al. Blood vessel fibronectin increases in conjunction with endothelial cell proliferation and capillary ingrowth during wound healing. J. Invest. Dermatol. 79 5 (1982) 269-276
90. Clark R.A., et al. Fibronectin and fibrin provide a provisional matrix for epidermal cell migration during wound reepithelialization. J. Invest. Dermatol. 79 5 (1982) 264-269
91. Grinnell F., Billingham R.E., and Burgess L. Distribution of fibronectin during wound healing in vivo. J. Invest. Dermatol. 76 3 (1981) 181-189
92. Mackie E.J., Halfter W., and Liverani D. Induction of tenascin in healing wounds. J. Cell Biol. 107 6 Pt 2 (1988) 2757-2767
93. Reed M.J., et al. Differential expression of SPARC and thrombospondin 1 in wound repair: immunolocalization and in situ hybridization. J. Histochem. Cytochem. 41 10 (1993) 1467-1477
94. Clark R.A.F., et al. Fibronectin beneath reepithelializing epidermis in vivo: sources and significance. J. Invest. Dermatol. 80 (1983) 26S-30S (suppl)
95. George E.L., et al. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 119 (1993) 1079-1091
96. Sakai T., et al. Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. Nat. Med. 7 3 (2001) 324-330
97. Grinnell F., and Zhu M. Identification of neutrophil elastase as the proteinase in burn wound fluid responsible for degradation of fibronectin. J. Invest. Dermatol. 103 2 (1994) 155-161
98. Herrick S.E., et al. Venous ulcer fibroblasts compared with normal fibroblasts show differences in collagen but not fibronectin production under both normal and hypoxic conditions. J. Invest. Dermatol. 106 1 (1996) 187-193
99. Wysocki A.B., and Grinnell F. Fibronectin profiles in normal and chronic wound fluid. Lab. Invest. 63 6 (1990) 825-831
100. Grinnell F., Ho C.H., and Wysocki A. Degradation of fibronectin and vitronectin in chronic wound fluid: analysis by cell blotting, immunoblotting, and cell adhesion assays. J. Invest. Dermatol. 98 4 (1992) 410-416
101. Trengove N.J., et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen. 7 6 (1999) 442-452
102. Wysocki A.B., Staiano-Coico L., and Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J. Invest. Dermatol. 101 1 (1993) 64-68
103. Zhang Z., et al. The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc. Natl. Acad. Sci. U. S. A. 92 13 (1995) 6161-6165
104. Zhu X., et al. Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J. Cell Biol. 133 2 (1996) 391-403
105. Longaker M.T., et al. Studies in fetal wound healing. V. A prolonged presence of hyaluronic acid characterizes fetal wound fluid. Ann. Surg. 213 4 (1991) 292-296
106. Welch M.P., Odland G.F., and Clark R.A. Temporal relationships of F-actin bundle formation, collagen and fibronectin matrix assembly, and fibronectin receptor expression to wound contraction. J. Cell Biol. 110 1 (1990) 133-145
107. Greiling D., and Clark R.A.F. Fibronectin provides a conduit for fibroblast transmigration from a collagen gel into a fibrin gel. J. Cell Sci. 110 Pt 7 (1997) 861-870
108. Ghosh K., et al. Fibronectin functional domains coupled to hyaluronan stimulate adult human dermal fibroblast responses critical for wound healing. Tissue Eng. 12 3 (2006) 601-613
109. Gui Y., and Murphy L.J. Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) binds to fibronectin (FN): demonstration of IGF-I/IGFBP-3/fn ternary complexes in human plasma. J. Clin. Endocrinol. Metab. 86 5 (2001) 2104-2110
110. Alon R., et al. TNF-alpha binds to the N-terminal domain of fibronectin and augments the beta 1-integrin-mediated adhesion of CD4 + T lymphocytes to the glycoprotein. J. Immunol. 152 3 (1994) 1304-1313
111. Wijelath E.S., et al. Novel vascular endothelial growth factor binding domains of fibronectin enhance vascular endothelial growth factor biological activity. Circ. Res. 91 1 (2002) 25-31
112. Rahman S., et al. Novel hepatocyte growth factor (HGF) binding domains on fibronectin and vitronectin coordinate a distinct and amplified Met-integrin induced signalling pathway in endothelial cells. BMC Cell Biol. 6 1 (2005) 8
113. Wijelath E.S., et al. Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. Circ. Res. 99 8 (2006) 853-860
114. Dallas S.L., et al. Fibronectin regulates latent transforming growth factor-beta (TGF beta) by controlling matrix assembly of latent TGF beta-binding protein-1. J. Biol. Chem. 280 19 (2005) 18871-18880
115. Lane D.A., et al. Structural requirements for the neutralization of heparin-like saccharides by complement S protein/vitronectin. J. Biol. Chem. 262 34 (1987) 16343-16348
116. Gebb C., et al. Interaction of vitronectin with collagen. J. Biol. Chem. 261 35 (1986) 16698-16703
117. Upton Z., et al. Identification of vitronectin as a novel insulin-like growth factor-II binding protein. Endocrinology 140 6 (1999) 2928-2931
118. Noble A., et al. Insulin-like growth factor-II bound to vitronectin enhances MCF-7 breast cancer cell migration. Endocrinology 144 6 (2003) 2417-2424
119. Kricker J.A., et al. Structural and functional evidence for the interaction of insulin-like growth factors (IGFs) and IGF binding proteins with vitronectin. Endocrinology 144 7 (2003) 2807-2815
120. Nam T., Moralez A., and Clemmons D. Vitronectin binding to IGF binding protein-5 (IGFBP-5) alters IGFBP-5 modulation of IGF-I actions. Endocrinology 143 1 (2002) 30-36
121. Schoppet M., et al. Molecular interactions and functional interference between vitronectin and transforming growth factor-beta. Lab. Invest. 82 1 (2002) 37-46
122. Peng H., et al. Identification of a binding site on human FGF-2 for fibrinogen. Blood 103 6 (2004) 2114-2120
123. Sporn L.A., Bunce L.A., and Francis C.W. Cell proliferation on fibrin: modulation by fibrinopeptide cleavage. Blood 86 5 (1995) 1802-1810
124. Chalupowicz D.G., et al. Fibrin II induces endothelial cell capillary tube formation. J. Cell Biol. 130 1 (1995) 207-215
125. Sahni A., Odrljin T., and Francis C.W. Binding of basic fibroblast growth factor to fibrinogen and fibrin. J. Biol. Chem. 273 13 (1998) 7554-7559
126. Sahni A., Sporn L.A., and Francis C.W. Potentiation of endothelial cell proliferation by fibrin(ogen)-bound fibroblast growth factor-2. J. Biol. Chem. 274 21 (1999) 14936-14941
127. Sahni A., and Francis C.W. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood 96 12 (2000) 3772-3778
128. Vlodavsky I., et al. Aortic endothelial cells synthesize basic fibroblast growth factor which remains cell associated and platelet-derived growth factor-like protein which is secreted. J. Cell. Physiol. 131 3 (1987) 402-408
129. Sahni A., Sahni S.K., and Francis C.W. Endothelial cell activation by IL-1beta in the presence of fibrinogen requires alphavbeta3. Arterioscler. Thromb. Vasc. Biol. 25 10 (2005) 2222-2227
130. Somasundaram R., and Schuppan D. Type I, II, III, IV, V, and VI collagens serve as extracellular ligands for the isoforms of platelet-derived growth factor (AA, BB, and AB). J. Biol. Chem. 271 43 (1996) 26884-26891
131. Nugent M.A., and Newman M.J. Inhibition of normal rat kidney cell growth by transforming growth factor-beta is mediated by collagen. J. Biol. Chem. 264 30 (1989) 18060-18067
132. Paralkar V.M., Vukicevic S., and Reddi A.H. Transforming growth factor beta type 1 binds to collagen IV of basement membrane matrix: implications for development. Dev. Biol. 143 2 (1991) 303-308
133. Schuppan D., et al. Collagens in the liver extracellular matrix bind hepatocyte growth factor. Gastroenterology 114 1 (1998) 139-152
134. Termine J.D., et al. Osteonectin, a bone-specific protein linking mineral to collagen. Cell 26 1 Pt 1 (1981) 99-105
135. Mann K., et al. Solubilization of protein BM-40 from a basement membrane tumor with chelating agents and evidence for its identity with osteonectin and SPARC. FEBS Lett. 218 1 (1987) 167-172
136. Sage E.H., et al. Inhibition of endothelial cell proliferation by SPARC is mediated through a Ca(2+)-binding EF-hand sequence. J. Cell. Biochem. 57 1 (1995) 127-140
137. Brekken R.A., and Sage E.H. SPARC, a matricellular protein: at the crossroads of cell-matrix. Matrix Biol. 19 7 (2000) 569-580
138. Raines E.W., et al. The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and-BB and inhibits the binding of PDGF to its receptors. Proc. Natl. Acad. Sci. U. S. A. 89 4 (1992) 1281-1285
139. Kupprion C., Motamed K., and Sage E.H. SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J. Biol. Chem. 273 45 (1998) 29635-29640
140. Hasselaar P., and Sage E.H. SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells. J. Cell. Biochem. 49 3 (1992) 272-283
141. Francki A., et al. SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. J. Cell. Biochem. 91 5 (2004) 915-925
142. Motamed K., Angello J., Hauschka S., and Sage E.H. Fibroblast growth factor receptor (FGFR)-1 mediates the inhibition of endothelial cell proliferation and promotion of skeletal myoblast differentiation by SPARC. FASEB J. 13 (1999) A704
143. Heldin C.H., Miyazono K., and ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390 6659 (1997) 465-471
144. Bradshaw A.D., Reed M.J., and Sage E.H. SPARC-null mice exhibit accelerated cutaneous wound closure. J. Histochem. Cytochem. 50 1 (2002) 1-10
145. Sage E.H. Regulation of interactions between cells and extracellular matrix: a command performance on several stages. J. Clin. Invest. 107 7 (2001) 781-783
146. Bagavandoss P., and Wilks J.W. Specific inhibition of endothelial cell proliferation by thrombospondin. Biochem. Biophys. Res. Commun. 170 2 (1990) 867-872
147. Taraboletti G., et al. Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J. Cell Biol. 111 2 (1990) 765-772
148. Vogel T., et al. Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin. J. Cell. Biochem. 53 1 (1993) 74-84
149. Majack R.A., Cook S.C., and Bornstein P. Control of smooth muscle cell growth by components of the extracellular matrix: autocrine role for thrombospondin. Proc. Natl. Acad. Sci. U. S. A. 83 23 (1986) 9050-9054
150. Phan S.H., et al. Stimulation of fibroblast proliferation by thrombospondin. Biochem. Biophys. Res. Commun. 163 1 (1989) 56-63
151. Barnard J.A., Lyons R.M., and Moses H.L. The cell biology of transforming growth factor beta. Biochim. Biophys. Acta 1032 1 (1990) 79-87
152. Keski-Oja J., et al. Transforming growth factors and control of neoplastic cell growth. J. Cell. Biochem. 33 2 (1987) 95-107
153. Roberts A.B., and Sporn M.B. Transforming growth factor beta. Adv. Cancer Res. 51 (1988) 107-145
154. Sporn M.B., et al. Transforming growth factor-beta: biological function and chemical structure. Science 233 4763 (1986) 532-534
155. Schultz-Cherry S., and Murphy-Ullrich J.E. Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism. J. Cell Biol. 122 4 (1993) 923-932
156. Schultz-Cherry S., et al. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. J. Biol. Chem. 269 43 (1994) 26775-26782
157. Schultz-Cherry S., et al. Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J. Biol. Chem. 270 13 (1995) 7304-7310
158. Ribeiro S.M., et al. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta. J. Biol. Chem. 274 19 (1999) 13586-13593
159. Young G.D., and Murphy-Ullrich J.E. Molecular interactions that confer latency to transforming growth factor-beta. J. Biol. Chem. 279 36 (2004) 38032-38039
160. Weber P., et al. Tenascin-C binds heparin by its fibronectin type III domain five. J. Biol. Chem. 270 9 (1995) 4619-4623
161. Swindle C.S., et al. Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. J. Cell Biol. 154 2 (2001) 459-468
162. Salmivirta M., et al. Syndecan from embryonic tooth mesenchyme binds tenascin. J. Biol. Chem. 266 12 (1991) 7733-7739
163. Wiik H.T., et al. Increased postoperative concentrations of tenascin-C in wound fluid. J. Trauma 56 4 (2004) 901-905
164. Midwood K.S., et al. Modulation of cell-fibronectin matrix interactions during tissue repair. J. Investig. Dermatol. Symp. Proc. 11 1 (2006) 73-78
165. Orend G., et al. Tenascin-C blocks cell-cycle progression of anchorage-dependent fibroblasts on fibronectin through inhibition of syndecan-4. Oncogene 22 25 (2003) 3917-3926
166. Midwood K.S., and Schwarzbauer J.E. Tenascin-C modulates matrix contraction via focal adhesion kinase-and Rho-mediated signaling pathways. Mol. Biol. Cell 13 10 (2002) 3601-3613
167. Forsberg E., et al. Skin wounds and severed nerves heal normally in mice lacking tenascin-C. Proc. Natl. Acad. Sci. U. S. A. 93 13 (1996) 6594-6599
168. Clark R.A., et al. Fibroblast migration on fibronectin requires three distinct functional domains. J. Invest. Dermatol. 121 4 (2003) 695-705
169. Liu Y., et al. Release of basic fibroblast growth factor from a crosslinked glycosaminoglycan hydrogel promotes wound healing. Wound Repair Regen. 15 2 (2007) 245-251
170. Kirker K.R., et al. Glycosaminoglycan hydrogel films as bio-interactive dressings for wound healing. Biomaterials 23 17 (2002) 3661-3671
171. Yayon A., et al. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64 4 (1991) 841-848
172. Zisch A.H., et al. Covalently conjugated VEGF-fibrin matrices for endothelialization. J. Control. Release 72 1-3 (2001) 101-113
173. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med. 77 7 (1999) 527-543
174. Ehrbar M., et al. Endothelial cell proliferation and progenitor maturation by fibrin-bound VEGF variants with differential susceptibilities to local cellular activity. J. Control. Release 101 1-3 (2005) 93-109
175. Schleicher I., et al. Surface modification by complexes of vitronectin and growth factors for serum-free culture of human osteoblasts. Tissue Eng. 11 11-12 (2005) 1688-1698
176. Green H., Kehinde O., and Thomas J. Growth of cultured human epidermal cells into multiple epithelia suitable for grafting. Proc. Natl. Acad. Sci. U. S. A. 76 11 (1979) 5665-5668
177. Dawson R.A., et al. Preparation of cultured skin for transplantation using insulin-like growth factor I in conjunction with insulin-like growth factor binding protein 5, epidermal growth factor, and vitronectin. Transplantation 81 12 (2006) 1668-1676
178. 1993. Wound Care in the US: Emerging trends, management and new product development. Medical Data International, Inc.